2018
Prospective plasma efavirenz concentration assessment in Chinese HIV‐infected adults enrolled in a large multicentre study
Guo F, Cheng X, Hsieh E, Du X, Fu Q, Peng W, Li Y, Song X, Routy J, Li T. Prospective plasma efavirenz concentration assessment in Chinese HIV‐infected adults enrolled in a large multicentre study. HIV Medicine 2018, 19: 440-451. PMID: 29761920, PMCID: PMC6538474, DOI: 10.1111/hiv.12607.Peer-Reviewed Original ResearchLower body weightEfavirenz concentrationsBody weightWeek 4Chinese HIVMedian efavirenz concentrationPlasma efavirenz concentrationsAntiretroviral therapy initiationProspective multicentre trialProportion of patientsLarge multicentre studyPlasma samplesMultivariable regression analysisHigh efavirenz concentrationsNon-Han ethnicityEfavirenz 600Therapy initiationMulticentre trialMulticentre studyDosage reductionOptimal dosingTherapeutic windowPatientsSubstantial proportionHIV
2016
Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV
Hsieh E, Fraenkel L, Han Y, Xia W, Insogna KL, Yin MT, Zhu T, Cheng X, Li T. Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV. AIDS 2016, 30: 1935-1942. PMID: 27124896, PMCID: PMC4949136, DOI: 10.1097/qad.0000000000001131.Peer-Reviewed Original ResearchConceptsTenofovir disoproxil fumarateVitamin DProcollagen type 1 N-terminal propeptideInitiation of TDFTenofovir/lamivudine/efavirenzVitamin D binding protein (VDBP) levelsCollagen type 1 cross-linked C-telopeptideIntact parathyroid hormone levelsCross-linked C-telopeptideIntact parathyroid hormoneParathyroid hormone levelsTotal procollagen type 1 N-terminal propeptideBinding protein levelsProtein levelsMulticenter clinical trialPlasma samplesOngoing multicenter clinical trialsN-terminal propeptideClinical characteristicsParathyroid hormoneBone lossFormation markersDisoproxil fumarateC-telopeptideBone resorption
2014
Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIV
Hsieh E, Fraenkel L, Xia W, Hu YY, Han Y, Insogna K, Yin MT, Xie J, Zhu T, Li T. Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIV. Osteoporosis International 2014, 26: 1035-1044. PMID: 25224293, PMCID: PMC4334679, DOI: 10.1007/s00198-014-2874-3.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusLopinavir/ritonavirBone turnover markersBone resorption marker levelsResorption marker levelsNon-Chinese populationsAntiretroviral therapyTreatment failureImmunodeficiency virusMarker levelsSkeletal metabolismC-terminal cross-linking telopeptideLopinavir/ritonavir therapyTreatment-naïve patientsFirst-line therapyBone resorption markersProcollagen type 1Multi-center trialPlasma samplesChinese individualsN-terminal propeptideType 1 collagenRitonavir therapyTurnover markersResorption markers